Sponsor:
Incyte Corporation
Code:
NCT07623200
Conditions
Essential Thrombocythemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
INCA033989
Best Available Treatment
Brief summary:
Conditions
Essential Thrombocythemia
Study ID
NCT07623200
Start date
Sep 8, 2026
Status verified date
Nov, 2026
Completion date
Nov 1, 2030
Anticipated
Primary completion date
Jun 15, 2029
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
426 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: INCA033989
experimental: Best Available Therapy (BAT)
Interventions
INCA033989
Best Available Treatment
Primary outcome measure
Central contacts
Locations
City of Hope Medical Center
Recruiting
Duarte, California, United States, 91010
Marin Cancer Care
Recruiting
Greenbrae, California, United States, 94904
Maryland Oncology Hematology, P.A.
Recruiting
Columbia, Maryland, United States, 21044
Willamette Valley Cancer Institute and Research Center
Recruiting
Eugene, Oregon, United States, 97401
Texas Oncology-Tyler
Recruiting
Tyler, Texas, United States, 75702
University Health Network (Uhn) - Princess Margaret Cancer Centre
Recruiting
Toronto, Ontario, Canada, M5G 2M9
Sponsor
Incyte Corporation
Last update posted
Nov 13, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Incyte Corporation on 2026-11-13. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.